Table 2.
Descriptive Characteristics of Study Sample, by CCOP Exposure.
| All stage III Colon Cancer Patients | CCOP Patients | non CCOP Patients | CCOP vs. non-CCOP3 | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| n | (%) | n | (%) | n | (%) | ||
| Patient Characteristics | 4054 | 1029 | (25.4%) | 3025 | (74.6%) | ||
|
| |||||||
| Gender | |||||||
| Male | 1728 | (42.6%) | 430 | (41.8%) | 1298 | (42.9%) | |
| Female | 2326 | (57.4%) | 599 | (58.2%) | 1727 | (57.1%) | |
| Race | |||||||
| Caucasian American | 3519 | (86.8%) | 881 | (85.6%) | 2638 | (87.2%) | |
| African American | 316 | (7.8%) | 84 | (8.2%) | 232 | (7.7%) | |
| Other/Unknown | 219 | (5.4%) | 64 | (6.2%) | 155 | (5.1%) | |
| Age (in years) | |||||||
| Mean (SD); (Range) | 77.56 (6.95) | (66–105) | 76.86 (6.79) | (66–98) | 77.79 (6.99) | (66–105) | |
| 65–69 | 597 | (14.7%) | 165 | (16.0%) | 432 | (14.3%) | |
| 70–74 | 862 | (21.3%) | 256 | (24.9%) | 606 | (20.0%) | |
| 75–79 | 1022 | (25.2%) | 249 | (24.2%) | 773 | (25.6%) | |
| 80–84 | 889 | (21.9%) | 208 | (20.2%) | 681 | (22.5%) | |
| 85+ | 684 | (16.9%) | 151 | (14.7%) | 533 | (17.6%) | |
| Income1 | |||||||
| Quartile 1: lowest income | 1056 | (26.0%) | 246 | (23.9%) | 810 | (26.8%) | *** |
| Quartile 2: low-med income | 1039 | (25.6%) | 229 | (22.3%) | 810 | (26.8%) | |
| Quartile 3: med-high income | 1021 | (25.2%) | 277 | (26.9%) | 744 | (24.6%) | |
| Quartile 4: highest income | 938 | (23.1%) | 277 | (26.9%) | 661 | (21.9%) | |
| Education2 | |||||||
| Quartile 1: lowest education | 1017 | (25.1%) | 222 | (21.6%) | 795 | (26.3%) | ** |
| Quartile 2: low-med education | 1047 | (25.8%) | 285 | (27.7%) | 762 | (25.2%) | |
| Quartile 3: med-high education | 1050 | (25.9%) | 275 | (26.7%) | 775 | (25.6%) | |
| Quartile 4: highest education | 940 | (23.2%) | 247 | (24.0%) | 693 | (22.9%) | |
| NCI combined comorbidity index | |||||||
| Mean (SD); (Range) | 0.27 (0.46) | (0–3.66) | 0.26 (0.46) | (0–2.61) | 0.27 (0.46) | (0–3.66) | |
| Primary site of tumor | |||||||
| Cecum, Ascending | 2042 | (50.4%) | 534 | (51.9%) | 1508 | (49.9%) | ** |
| Flexures, Transv./Descend. | 939 | (23.2%) | 253 | (24.6%) | 686 | (22.7%) | |
| Large intestine/NOS | 79 | (1.9%) | 12 | (1.2%) | 67 | (2.2%) | |
| Sigmoid | 994 | (24.5%) | 230 | (22.4%) | 764 | (25.3%) | |
| Tumor grade | |||||||
| Well-differentiated | 186 | (4.6%) | 55 | (5.3%) | 131 | (4.3%) | * |
| Moderately differentiated | 2537 | (62.6%) | 640 | (62.2%) | 1897 | (62.7%) | |
| Poorly differentiated | 1152 | (28.4%) | 277 | (26.9%) | 875 | (28.9%) | |
| Unknown | 179 | (4.4%) | 57 | (5.5%) | 122 | (4.0%) | |
| Year of Chemo | |||||||
| no chemo | 1537 | (37.9%) | 337 | (32.8%) | 1200 | (39.7%) | *** |
| 2003 | 775 | (19.1%) | 215 | (20.9%) | 560 | (18.5%) | |
| 2004 | 813 | (20.1%) | 228 | (22.2%) | 585 | (19.3%) | |
| 2005 | 800 | (19.7%) | 218 | (21.2%) | 582 | (19.2%) | |
| 2006 | 129 | (3.2%) | 31 | (3.0%) | 98 | (3.2%) | |
| Dual eligibility | |||||||
| Yes | 707 | (17.4%) | 141 | (13.7%) | 566 | (18.7%) | *** |
|
| |||||||
| Organization characteristics (of treating hospital) | |||||||
|
| |||||||
| Cooperative Group Affiliation | |||||||
| Mean (SD); (Range) | 1.47 (1.62) | (0–9) | 1.68 (1.64) | (0–9) | 1.39 (1.61) | (0–8) | *** |
| No affiliation | 1649 | (40.7%) | 368 | (35.8%) | 1281 | (42.3%) | *** |
| Affiliated with 1+ C.G. | 2405 | (59.3%) | 661 | (64.2%) | 1744 | (57.7%) | |
| Medical School affiliation | |||||||
| Unaffiliated | 3237 | (79.8%) | 831 | (80.8%) | 2406 | (79.5%) | |
| Limited | 817 | (20.2%) | 198 | (19.2%) | 619 | (20.5%) | |
| NCI-center affiliated | |||||||
| Yes | <11 | (<1%) | <11 | (<1%) | <11 | (<1%) | |
|
| |||||||
| Outcome | |||||||
|
| |||||||
| 5-Fu | 1432 | (35.3%) | 361 | (35.1%) | 1071 | (35.4%) | *** |
| Folfox/Oxaliplatin | 821 | (20.3%) | 255 | (24.8%) | 566 | (18.7%) | |
| Other or Unknown Chemotherapy | 264 | (6.5%) | 76 | (7.4%) | 188 | (6.2%) | |
| No chemo | 1537 | (37.9%) | 337 | (32.8%) | 1200 | (39.7%) | |
Median household income in patient’s census tract.
Proportion of patient’s census tract population with high school education or greater.
Chi-square test (categorial) or t-test (continuous):
p<0.01: ***,
p<0.05: **,
p<0.10: *
-SEER regions were examined but are not reported. The distribution of patients seen by CCOPs vs. non-CCOPs differed by region (p<0.01)
-Specific comorbidities were examined but not reported. There were no differences among patients seen by CCOPs vs. non-CCOPs
-Per SEER-Medicare data use requirements, methods were used to suppress cell sizes smaller than 11, and included collapsing some categories of measures, using “<11” to reflect small numbers, and partially masking values to prevent mathematical derivation of small numbers.